|Bid||33.67 x 1100|
|Ask||33.71 x 800|
|Day's Range||32.50 - 33.84|
|52 Week Range||16.69 - 41.33|
|Beta (3Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
- Sequential release of topline pivotal Phase 3 data readouts expected to start in second half of the third quarter
NEW YORK, NY / ACCESSWIRE / July 24, 2019 / The Medicines Co. (NASDAQ: MDCO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 8:30 AM Eastern ...
The Medicines Company will host a conference call and audio webcast on Wednesday, July 24, 2019 at 8:30 a.m. EDT to discuss its second quarter 2019 financial results and operational developments.
The Medicines Company (MDCO) (the “Company”) today announced the pricing of a public offering of 4,545,455 shares of its common stock at a public offering price of $33.00 per share. Gross proceeds of the offering are expected to be approximately $150 million, before underwriting discounts and commissions and other transaction expenses. In addition, the underwriters have been granted a 30-day option to purchase from the Company up to an additional 681,818 shares of common stock.
The Medicines Company (MDCO) (the “Company”) today announced the launch of a public offering of $150.0 million of shares of its common stock. In addition, the underwriters will be granted a 30-day option to purchase from the Company up to an additional $22.5 million of shares of common stock. The Company expects to use the net proceeds of the offering to fund its development of inclisiran and for general corporate purposes.
A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.
NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines Company (MDCO). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.
The Medicines Company (MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study.
The Medicines Company (MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company’s management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study.
The Medicines Company announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m.
$MDCO announces #Q12019 financial results and significant progress with #inclisiran clinical development program. Find audio webcast and replay @ https://mdco.co/nqdzt.
The Medicines Company will host a conference call and audio webcast on Thursday, April 25, 2019 at 8:30 a.m. EDT to discuss its first quarter 2019 financial results and operational developments.
$MDCO announces #Q42018 financial results and progress with ORION development program. Find the webcast and replay @ https://mdco.co/oeiqw
The Medicines Company announced today that management will present company overviews at the following conferences:
The Medicines Company will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.m. EST to discuss its fourth-quarter and full-year 2018 financial results and operational developments.
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
With full commercial rights in all geographies, The Medicines Company is well placed to harness the intrinsic value of inclisiran. To date, more than 2,450 patient-years of inclisiran safety data have been accumulated in the ORION program, a seven-fold (or 2,120 patient-year) increase over the total patient exposure from the ORION Phase 1 and Phase 2 trials. At the time of IDMC review, all patients in Phase 3 trials had received three doses of inclisiran or placebo.
The Medicines Company (MDCO) (the “Company”) today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024. The notes will be senior unsecured obligations of the Company and will mature on January 15, 2024, unless earlier converted or repurchased in accordance with their terms. The notes will be convertible prior to October 15, 2023 only upon the occurrence of certain circumstances and will be convertible thereafter regardless of these circumstances, in either case, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option.
The Medicines Company (MDCO) (the “Company”) today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors. The notes will be convertible, upon certain conditions, into cash, shares of the Company’s common stock or a combination thereof, at the Company’s option. The interest rate, conversion rate, offering price and other terms will be determined by negotiations among the Company and J.P. Morgan Securities LLC, the initial purchaser of the notes.
The Medicines Company (MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company’s new Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the Board to serve as Chief Innovation Officer. Alexander Denner, Ph.D., the Chairman of the Board of Directors, stated, “We are pleased to welcome Mark Timney as our new CEO.
The Medicines Company is a biopharmaceutical company driven by an overriding purpose – to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care.
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Medicines Company will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.m., EST, to discuss its third-quarter 2018 financial results and operational developments.